---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-008163"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:28:18.024293+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Insmed reports Q4 2022 ARIKAYCE revenue $59.3M, full year $245.4M; net loss $1.21 per share

## Summary
- ARIKAYCE global revenue grew 30% in 2022 to $245.4M; Q4 revenue $59.3M, impacted by $7.5M French pricing adjustment.
- Net loss for Q4 2022 was $160.1M ($1.21/share) vs $113.0M ($0.95/share) in Q4 2021; full year net loss $481.5M ($3.91/share).
- Phase 3 ASPEN trial of brensocatib in bronchiectasis completed adult patient screening; topline data expected Q2 2024.
- Company guides 2023 ARIKAYCE global revenue $285-300M; cash position $1.15B as of Dec 31, 2022.
- ARISE study topline data expected Q3 2023; ENCORE enrollment by end 2023; early-stage research update May 8, 2023.

## SEC filing metadata
- accession: 0001140361-23-008163
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/0001140361-23-008163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/brhc10048554_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-008163
- JSON: https://secwatch.observer/filing/0001140361-23-008163.json
- Plain text: https://secwatch.observer/filing/0001140361-23-008163.txt

## Key facts
- Earnings Releases
  INSMED Inc reported the fourth quarter ended December 31, 2022 results: revenue $59.3 million, net income net loss of $160.1 million, EPS $1.21 per share.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $59.3 million
  - Net income: net loss of $160.1 million
  - EPS: $1.21 per share
  - Result: reported results
  source text: on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE ® (amikacin liposome inhalation suspension) in Third Quarter of 2023— —ARIKAYCE Total Revenue of $59.3 Million for the Fourth Quarter and $245.4 Million for the Full Year 2022, Reflecting 30% Annual Growth— BRIDGEWATER, N.J., February 23, 2023 /PRNewswire/ — Insmed Incorporated
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/0001140361-23-008163-index.htm
- Earnings Releases
  INSMED Inc reported the full year ended December 31, 2022 results: revenue $245.4 million, net income net loss of $481.5 mill.
  - Period: the full year ended December 31, 2022
  - Revenue: $245.4 million
  - Net income: net loss of $481.5 mill
  - Result: reported results
  source text: Total revenue for the full year 2022 was $245.4 million, compared to total revenue of $188.5 million for the full year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/0001140361-23-008163-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.